Rapamycin for healthy aging: what the PEARL trial actually found

Rapamycin (sirolimus) is a drug that inhibits a cellular signaling pathway called mTOR (mechanistic target of rapamycin), which regulates cell growth, metabolism, and a cleanup process called autophagy. It has been an FDA-approved immunosuppressant since 1999, prescribed under the brand name Rapamune to help prevent organ rejection after kidney transplants, and later approved to treat a rare lung disease called lymphangioleiomyomatosis.^[4] Interest in rapamycin as an anti-aging compound comes from a separate body of animal research, not from its approved transplant use, and that distinction matters throughout this article.

PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is a 48-week, decentralized, double-blind, randomized, placebo-controlled trial registered as NCT04488601.^[2] It randomized 125 adults aged 50 to 85 to weekly oral compounded rapamycin at 5mg or 10mg, or to a matching placebo; 114 participants (40 on 5mg, 35 on 10mg, 39 on placebo) completed the full 48 weeks, and 11 discontinued before completion.^[1] The trial was organized by the nonprofit Lifespan.io and the telehealth company AgelessRx, and its lead clinical investigator, Sajad Zalzala, MD, is a co-founder and Chief Medical Officer of AgelessRx.

Trials designate one outcome in advance as the primary endpoint, the measure the whole study is statistically powered to detect and the one that determines whether the trial is judged a success. PEARL’s primary endpoint was visceral adipose tissue, a marker of metabolically harmful abdominal fat, measured by DXA scan. After 48 weeks, visceral fat showed essentially no change relative to placebo (p=0.942).^[1] The trial authors suggested this may partly reflect who enrolled: the cohort was, in their own description, notably health-conscious at baseline, with a lower BMI range and healthier diet and exercise habits than a general population sample, which likely left less room to detect a meaningful reduction in visceral fat.^[1]

Several secondary, pre-specified outcomes did show statistically significant differences, but narrowly and unevenly across dose and sex. Among women, the 10mg group gained significantly more lean tissue mass than placebo, a mean difference of 6.194 percentage points at 48 weeks (95% CI 0.877 to 11.511, p=0.018), and reported significantly less pain at both 24 weeks (p=0.011) and 48 weeks (p<0.001), both compared with placebo.^[1] Two other self-reported measures moved in the 5mg group: general health scores improved significantly from that group’s own baseline (placebo did not significantly change on this measure), and emotional wellbeing scores improved significantly from baseline in the 5mg group, but placebo also improved significantly on emotional wellbeing over the same 48 weeks.^[1] That last result does not support a drug-specific effect. Men showed no significant improvement on lean mass or pain at either dose, and bone mineral density did not change significantly in any group.^[1]

A scattering of blood biomarkers and one gut-microbiome measure also reached statistical significance in specific dose-by-sex subgroups: modest increases in red blood cell count in the 5mg group, in blood urea nitrogen among men on 10mg, and in hemoglobin A1c among men on 5mg; a small decrease in blood carbon dioxide in the 10mg group and in calcium among men on 10mg; and increased markers of gut dysbiosis among men on 10mg.^[1] All values stayed within normal clinical ranges.

Adverse and serious adverse events occurred at similar rates across all three groups. Participants reported any adverse event at rates of 80.6% (10mg), 77.5% (5mg), and 87.2% (placebo); serious adverse events occurred in 1 person on 10mg, 2 on 5mg, and 3 on placebo.^[1] Gastrointestinal symptoms were somewhat more common in the rapamycin groups, and one case of anemia in the 5mg group resolved with treatment. The trial reported no new safety signals distinct from rapamycin’s known profile in transplant medicine.^[1]

PEARL does not measure aging directly. It did not track mortality, a validated biological-age clock, or any outcome that would let researchers say rapamycin slows aging in a defined, measurable sense; it tracked body composition, self-reported symptoms, and blood markers over less than a year. The authors also flagged that adherence to the once-weekly dosing schedule relied largely on self-report, and that diet and activity were captured only through broad self-reported measures rather than objective tracking.^[1]The compounded rapamycin used in the trial reached roughly one-third the blood concentration of the commercial Rapamune formulation after 24 hours, a pharmacokinetic detail that complicates comparing PEARL’s doses to rapamycin used in transplant medicine or in other research.^[1]

It also has not been independently replicated. One trial, however well conducted, is a single data point. That is the same caution that applies to our coverage of cardiorespiratory fitness and longevity, except that VO2max’s mortality association has been replicated across many large cohorts over decades, while PEARL’s secondary findings have not yet been tested a second time.

The reason rapamycin attracted longevity researchers in the first place is a well-replicated finding in mice, not in humans. A landmark 2009 study from the National Institute on Aging’s Interventions Testing Program fed encapsulated rapamycin to genetically heterogeneous mice starting at 600 days of age, roughly equivalent to a 60-year-old human, and found it extended median lifespan by 13% in females and 9% in males in the pooled dataset.^[3] The same research program has since replicated a lifespan benefit across multiple independent cohorts and doses, making rapamycin one of the most consistently reproduced lifespan-extending interventions in mammalian research.

Mouse lifespan studies are a genuinely strong preclinical signal, and they are also, by definition, evidence in mice. Translating a dosing strategy and a biological mechanism from a short-lived, genetically manipulable species to long-lived, genetically diverse humans has failed for many promising compounds before, which is exactly why a trial like PEARL, imperfect as it is, represents real progress toward an answer rather than a formality.

Rapamycin is not sold over the counter. It requires a prescription, and a number of telehealth clinics, including AgelessRx, now prescribe it off-label specifically for anti-aging purposes, typically at the low, intermittent doses PEARL tested. Off-label prescribing is legal in the United States when a licensed physician judges it appropriate, but it means the FDA has not reviewed the drug for that use, and no completed human trial, including PEARL, has demonstrated that it extends lifespan or reverses a validated marker of aging.^[4]

The funding behind PEARL is worth stating plainly: the trial was largely crowdfunded through Lifespan.io, with administrative and trial support, article publishing charges, and other fees covered by AgelessRx, and its lead clinical investigator co-founded that company.^[1] That does not make the trial’s data false; the underlying statistics are what they are. But it is a real financial interest in a positive result, from the same company selling the product the trial studied, and readers deciding how much weight to put on the findings deserve to know that.

Rapamycin is an immunosuppressant even at low doses, which carries real considerations that a healthy-aging framing can obscure.

PEARL is a genuinely important trial: the largest and longest randomized, placebo-controlled study of rapamycin for healthy aging in humans completed to date, and it found real, reassuring short-term safety data. It is also a trial that missed its own primary endpoint, produced secondary findings concentrated in small subgroups without correction for multiple comparisons, and was substantially supported by a company with a direct financial interest in the drug it studied. None of that erases the mouse data behind rapamycin’s reputation, which remains genuinely strong, but it does mean the human evidence has not yet caught up to the marketing built on top of it. See how we grade evidence strength across topics in our editorial and evidence standards, and follow our Longevity & Healthy Aging coverage as independent replication, or a larger confirmatory trial, develops.

Nothing here is a reason to start or avoid rapamycin on your own. That decision, like any decision involving an immunosuppressant taken outside its approved use, belongs in a conversation with a physician who can weigh your own health history against what this evidence actually shows, not against what it is sometimes marketed as showing.